Welcome to VIRTTU
VIRTTU Biologics is a clinical stage biotechnology company pioneering the development of viruses to treat cancer.
By remodeling a common virus we have developed and patented a series of novel therapies that have the potential to transform treatment and target many forms of cancer effectively.
Our most advanced programme, a unique cancer-destroying (oncolytic) virus, has the potential to radically change oncology therapy through its ability to seek out and multiply only in cancer cells: destroying them while leaving healthy cells unaffected.
We are now actively advancing the clinical development programme required to secure regulatory approval to market our lead programme, SEPREHVIR®, for use in cancer therapy.
Read our latest blog 'Oncolytic HSV and adult and paediatric glioma stem cells'
Oncolytic HSV in combination with the existing treatments look to have great potential in targeting resistant GSCs thereby improving outcomes for adults and children with HGGs.
Meet the Virttu Biologics team at BIO 2013
UK-Scotland Pavilion, Booth 4438, Hall C
Virttu Biologics at key BIO 2013 events
Virttu Biologics participating in two high profile BIO 2013 events 21st and 22nd April: International Cancer Cluster Showcase and breakfast session 'The Role of Open Innovation in Successful Global Partnerships'
- 04/04/2013 Virttu Biologics presents paper at Society for General Microbiology Spring Conference
New Abstracts from Virttu presented at SGM Spring Conference
Virttu Biologics had three abstracts accepted at this year's Society for General Microbiology Spring Conference; two as poster presentations and one as a paper presentation.
VIRTTU's lead programme SEPREHVIR®, a unique oncolytic virus, shows the potential to transform treatment and target many forms of cancer effectively.
We are conducting clinical studies in a wide range of cancer types in leading medical centres in the USA and Europe.